Montillo, M, Tedeschi, A, Gaidano, G, Coscia, M, Petrizzi, Vb, Orlandi, E, Cascavilla, N, Ghia, PAOLO PROSPERO, Motta, M, Gallamini, A, Frustaci, Am, Rossi, D, De Paoli, L, Nichelatti, M, Morra, E, Massaia, M.
Alemtuzumab has been extensively used in the salvage setting of chronic lymphocytic leukemia (CLL) resulting less effective on bulky lymphadenopathy.[1][1] Higher response rates have been achieved when combined with fludarabine and cyclophosphamide (FC), but this regimen has led to some safety
